Frontiers in Oncology | Cancer Immunity and Immunotherapy

Case Report

Published on 30 Sep 2024

Case report: Fatal hemoptysis after effective treatment with tislelizumab and anlotinib in pulmonary sarcomatoid carcinoma

in Cancer Immunity and Immunotherapy

Chen-Wei Pu
Yong-Fen Ma
Jing-Jing Peng
Zhen-Zhen Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1445358

956 views

Review

Published on 26 Sep 2024

Effects of intratumoral microbiota on tumorigenesis, anti-tumor immunity, and microbe-based cancer therapy

in Cancer Immunity and Immunotherapy

Jingwei Zheng

Frontiers in Oncology

doi 10.3389/fonc.2024.1429722

2,309 views

Original Research

Published on 26 Sep 2024

Value of the lung immune prognostic index in patients with advanced small cell lung cancer treated with programmed death-ligand 1 and programmed death-1 inhibitors in the Chinese alpine region

in Cancer Immunity and Immunotherapy

Meiling Zhang
Jingwei Hao
Yunjiao Wu
Ziyi Gao
Meng Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1411548

600 views

Editorial

Published on 26 Sep 2024

Editorial: Insights and implications of mechanisms shaping glioma immune landscape, immunotherapy resistance, and relevant translational research

in Cancer Immunity and Immunotherapy

Frontiers in Oncology

doi 10.3389/fonc.2024.1485761

450 views

Review

Published on 26 Sep 2024

Progression of oncolytic virus in liver cancer treatment

in Cancer Immunity and Immunotherapy

Xuesi Hua
Siyu Xuan
Yangyang Tang
Shilin You
Shang Zhao
Ye Qiu
Yinqing Li
Yongqing Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1446085

2,007 views

Original Research

Published on 24 Sep 2024

Exploring the impact of HDL and LMNA gene expression on immunotherapy outcomes in NSCLC: a comprehensive analysis using clinical & gene data

in Cancer Immunity and Immunotherapy

Jingru Li
Jingting Wang
Banwei Cao

Frontiers in Oncology

doi 10.3389/fonc.2024.1448966

1,042 views

Review

Published on 24 Sep 2024

The sympathetic nervous system shapes the tumor microenvironment to impair chemotherapy response

in Cancer Immunity and Immunotherapy

Annabel V. Manoleras
Erica K. Sloan
Aeson Chang

Frontiers in Oncology

doi 10.3389/fonc.2024.1460493

1,139 views
2 citations

Case Report

Published on 20 Sep 2024

Case report: Intrapleural plus systemic Tislelizumab injection combined chemotherapy in RET gene fusion-positive lung adenocarcinoma presenting refractory malignant pleural effusion

in Cancer Immunity and Immunotherapy

Dong Qiu
Xiao-Hui Zhang
Yang Wang
Cheng Chen

Frontiers in Oncology

doi 10.3389/fonc.2024.1404173

991 views
1 citation

Original Research

Published on 16 Sep 2024

Revealing the mechanisms of RAC3 in tumor aggressiveness, the immunotherapy response, and drug resistance in bladder cancer

in Cancer Immunity and Immunotherapy

Hanyuan Gao
Yanru Qiu
Xueqin Zheng

Frontiers in Oncology

doi 10.3389/fonc.2024.1466319

934 views

Case Report

Published on 16 Sep 2024

Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature

in Cancer Immunity and Immunotherapy

Hu Feng
Shasha Bi
Shanshan Sun
Hongbo Yang
Haoxing Zhou
Jingjing Mao

Frontiers in Oncology

doi 10.3389/fonc.2024.1367140

1,102 views
1 citation

Case Report

Published on 16 Sep 2024

Sintilimab-induced myocarditis suspected in a patient with esophageal cancer and followed septic shock: case report and literature review

in Cancer Immunity and Immunotherapy

Qihao Zhou
Zhiquan Qin
Guoqing Wu
Peiyuan Yan
Qunjiang Wang
Jing Qu
Jiahong Jiang

Frontiers in Oncology

doi 10.3389/fonc.2024.1465395

1,133 views
2 citations

Original Research

Published on 13 Sep 2024

DSP-0509, a TLR7 agonist, exerted synergistic anti-tumor immunity combined with various immune therapies through modulating diverse immune cells in cancer microenvironment

in Cancer Immunity and Immunotherapy

Yosuke Ota
Ryosaku Inagaki
Kentaro Sumida
Megumi Nakamura
Yasuhiro Nagai
Setsuko Yamamoto

Frontiers in Oncology

doi 10.3389/fonc.2024.1410373

1,566 views
1 citation

Hypothesis and Theory

Published on 06 Sep 2024

Hepatocellular carcinoma cells induce γδ T cells through metabolic reprogramming into tumor-progressive subpopulation

in Cancer Immunity and Immunotherapy

Jinkun Xia
Chaoyu Wang
Biao Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1451650

1,238 views

Original Research

Published on 04 Sep 2024

A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

in Cancer Immunity and Immunotherapy

Lev Demidov
Galina Kharkevich
Natalia Petenko
Vladimir Moiseenko
Svetlana Protsenko
Tatiana Semiglazova
Anastasia Zimina
Nadezhda Kovalenko
Natalia Fadeeva
Dmitry Kirtbaya

Frontiers in Oncology

doi 10.3389/fonc.2024.1385685

1,524 views

Brief Research Report

Published on 02 Sep 2024

KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies

in Cancer Immunity and Immunotherapy

Lara V. Graham
Jack G. Fisher
Amber D. P. Doyle
Ben Sale
Luis Del Rio
Albert J. E. French
Neema P. Mayor
Thomas R. Turner
Steven G. E. Marsh
Mark S. Cragg

Frontiers in Oncology

doi 10.3389/fonc.2024.1404051

1,521 views

Editorial

Published on 29 Aug 2024

Editorial: Infectious diseases and cancer: convergence and divergence between bacteria, viruses and helminths

in Cancer Immunity and Immunotherapy

Ana Elena Escorcia-Saucedo
Alberto N. Peón
Aldo Christiaan Jardínez-Vera
Luis I. Terrazas
José L. Medina-Franco

Frontiers in Oncology

doi 10.3389/fonc.2024.1471156

452 views

Navigation group

Articles

Case report: Fatal hemoptysis after effective treatment with tislelizumab and anlotinib in pulmonary sarcomatoid carcinoma

Effects of intratumoral microbiota on tumorigenesis, anti-tumor immunity, and microbe-based cancer therapy

Value of the lung immune prognostic index in patients with advanced small cell lung cancer treated with programmed death-ligand 1 and programmed death-1 inhibitors in the Chinese alpine region

Editorial: Insights and implications of mechanisms shaping glioma immune landscape, immunotherapy resistance, and relevant translational research

Progression of oncolytic virus in liver cancer treatment

Exploring the impact of HDL and LMNA gene expression on immunotherapy outcomes in NSCLC: a comprehensive analysis using clinical & gene data

The sympathetic nervous system shapes the tumor microenvironment to impair chemotherapy response

Case report: Intrapleural plus systemic Tislelizumab injection combined chemotherapy in RET gene fusion-positive lung adenocarcinoma presenting refractory malignant pleural effusion

Revealing the mechanisms of RAC3 in tumor aggressiveness, the immunotherapy response, and drug resistance in bladder cancer

Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature

Sintilimab-induced myocarditis suspected in a patient with esophageal cancer and followed septic shock: case report and literature review

DSP-0509, a TLR7 agonist, exerted synergistic anti-tumor immunity combined with various immune therapies through modulating diverse immune cells in cancer microenvironment

Hepatocellular carcinoma cells induce γδ T cells through metabolic reprogramming into tumor-progressive subpopulation

A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies

Editorial: Infectious diseases and cancer: convergence and divergence between bacteria, viruses and helminths